Vycellix TM, Inc. Their main focus is on enhancing and optimizing next-generation cell and gene-based therapies, specifically in the field of T cell and Natural Killer (NK) cell-based cancer therapies. Vycellix has developed several innovative platforms to revolutionize the field of cell therapy.

The VY-UC platform enables the generation of immune-privileged universal cells without altering the self-recognition components, eliminating the need for immune-suppressive drugs in allogeneic cell therapies. The VY-OZ platform significantly enhances gene transduction rates and modifies cells for advanced immunotherapies. The VY-M platform accelerates cell expansion, including immune cells, resulting in faster delivery of new cell therapies to patients.

Finally, the VY-X platform amplifies the tumor-killing capacity of T cells and NK cells by selectively upregulating cytotoxic mechanisms. These groundbreaking platforms were all discovered by scientists at the prestigious Karolinska Institutet (KI) in Sweden, which is globally recognized for its Nobel Assembly. Vycellix is also a collaborative partner in NextGenNK, an international Competence Center for the development of next-generation NK cell-based cancer immunotherapies.

Vycellix is dedicated to overcoming the limitations of current approaches to cell and gene therapies. By delivering optimal therapeutic outcomes for patients and enabling broad global adoption, they are leading the charge in revolutionizing the future of healthcare. For more information or to get in touch, you can contact Vycellix headquarters located on the Campus of H.

Lee Moffitt Cancer Center in Tampa, Florida, USA